Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Merck Stock Is Heating Up Today


Pharma giant Merck (NYSE: MRK) saw its shares rise by a healthy 9% in premarket trading Friday morning. That's equivalent to a $5 billion jump in market capitalization. 

What's juicing Merck's stock price this morning? Ahead of the opening bell, the company announced that its oral antiviral medication molnupiravir -- developed in conjunction with Ridgeback Biotherapeutics -- cut the risk of hospitalization for COVID-19 by half. This result reportedly comes from a planned interim analysis of a phase 3 trial of the drug in at-risk, nonhospitalized adult patients with mild-to-moderate COVID-19. Even more impressively, zero patients who received molnupiravir in the study passed away, whereas eight patient deaths were recorded in the placebo wing of the trial.

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
MRK
Share

Comments